Teclistamab impairs vaccine response to H. influenzae. (A) Response after vaccination against H. influenzae type B in patients treated with teclistamab (n = 17). Control groups were patients with NNMM on maintenance therapy after autologous stem cell transplantation (n = 22), patients with daratumumab-naive RRMM (n = 11), and patients with RRMM treated with a daratumumab-containing regimen (n = 20). Response rates were compared using Pearson χ2 test or Fisher exact test. (B) Peak specific IgG titers (μg/mL), assessed by enzyme-linked immunosorbent assay, after H. influenzae type B vaccination in the teclistamab-treated and control groups. Data are depicted as violin plots, indicating the distribution, including the median and interquartile range. Groups were compared using Kruskal-Wallis test with Dunns correction for multiple comparisons. RRMM-DARA naive, patients with daratumumab-naive RRMM; RRMM-DARA, patients with RRMM treated with a daratumumab-containing regimen; RRMM-TEC, patients with RRMM treated with teclistamab; ∗∗P < .01; ∗∗∗P < .001; and ∗∗∗∗P < .0001.
